Stratosvir is developing a viral immunotherapy that utilizes engineered oncolytic viruses to selectively replicate within solid tumors, delivering therapeutic payloads that stimulate and reprogram the immune system to target cancer cells. This approach addresses the limitations of current treatment methods by enabling systemic delivery of cancer therapies, enhancing patient outcomes and quality of life.
Funding
$330K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment methods often struggle with systemic delivery of therapies to solid tumors, limiting their effectiveness and impacting patient outcomes and quality of life. Intratumoral injection, while effective in some cases, restricts the clinical use of many therapeutic viruses.
Solution
Stratosvir is developing a viral immunotherapy platform that utilizes engineered oncolytic viruses designed to selectively replicate within solid tumors. These viruses deliver therapeutic payloads directly into the tumor microenvironment, stimulating and reprogramming the patient's immune system to recognize and destroy cancer cells. The platform aims to overcome the limitations of existing systemic delivery methods, enabling intravenous administration of the cancer-killing virus. This approach enhances the potential for broad application across a range of solid tumors and their metastases.
Target Audience
The primary target audience includes cancer patients with solid tumors and the oncologists and medical professionals who treat them.
Features
- Engineered oncolytic viruses optimized for selective replication within tumor cells.
- Systemic delivery platform designed to overcome barriers to intravenous administration.
- Therapeutic payloads delivered directly to the tumor microenvironment.
- Stimulation and reprogramming of the immune system to target cancer cells.